Recombinant Human NEDD8 (N-6His-SUMO) from ELK Biotechnology Read more ›
Recombinant Human NEDD8 (N-6His-SUMO) is a research-use recombinant protein from ELK Biotechnology preparation representing NEDD8 supplied as Lyophilized. Review the expression, purity, formulation and storage specifications below before selecting it for an assay or functional workflow.
Recombinant Human Neural Precursor Cell Expressed Developmentally Down-regulated Protein 8 is produced by our E.coli expression system and the target gene encoding Met1-Gly76 is expressed with a 6His, SUMO tag at the N-terminus.
Human NEDD8 shares 60% amino acid sequence identity to ubiquitin. The only known substrates of NEDD8 modification are the cullin subunits of SCF ubiquitin E3 ligases. The NEDDylation of cullins is critical for the recruitment of E2 to the ligase complex, thus facilitating ubiquitin conjugation. NEDD8 modification has therefore been implicated in cell cycle progression and cytoskeletal regulation.
| Reconstitution | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100µg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
|---|---|
| Delivery condition | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. |
| Collaborator | ELK Biotechnology |
| Partner model | EPT278 |
| Target | NEDD8 |
| Research areas | Molecular Biology |
| Reactivity | Product QC:C |
| Applications | Protein research |
| Assay type | Recombinant protein |
| Purity | >95% by SDS-PAGE |
| Endotoxin | Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test. |
| Category | Purity | Endotoxin | Bioactivity |
|---|---|---|---|
| Product QC |
Collaborator meets ABMIUM quality standards and overall product performance standards have been met.
Quality management certification.
For research applications. Not for diagnostic use.
No customer reviews yet.
